article thumbnail

Pharmacist Involvement Helps Reduce Time to A1c Target

Drug Topics

J Am Pharm Assoc (2003). Sign up today for our free Drug Topics newsletter. References 1. Osunsanmi O, Schmitz N, Darkwah B, et al. Time to goal hemoglobin A1c with pharmacist management compared to non-pharmacist management. 2025 May 6:102413. doi: 10.1016/j.japh.2025.102413. 2025.102413. Epub ahead of print. PMID: 40339647.

article thumbnail

Elevating Pharmacy Technicians in Community Practice

Drug Topics

J Am Pharm Assoc (2003). I think a lot of pharmacists know that and even some of the ones who maybe aren't as quick to acknowledge it for whatever reason also recognize that.” References 1. Fick G, Osei J, Kim S, et al. A narrative literature review: Community pharmacy technician well-being and its implications. 2025 May 9:102419.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients

Pharmacy Times

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

FDA 144
article thumbnail

FDA approves Biogen’s Alzheimer's drug, Aduhelm

Outsourcing Pharma

The US Food and Drug Administration (FDA) has approved Biogenâs Aduhelm (aducanumab) for the treatment of Alzheimerâs: making it the first new treatment approved for the disease since 2003.

FDA 98
article thumbnail

Q&A: Prioritizing Pharmacy Technician Well-Being

Drug Topics

J Am Pharm Assoc (2003). READ MORE: Supporting the Well-Being of Community Pharmacy Technicians References 1. Fick G, Osei J, Kim S, et al. A narrative literature review: Community pharmacy technician well-being and its implications. 2025 May 9:102419. doi: 10.1016/j.japh.2025.102419. 2025.102419. Epub ahead of print. PMID: 40349976.

article thumbnail

FDA approves Wezlana for inflammatory conditions

The Checkup by Singlecare

Food and Drug Administration (FDA) just approved Wezlana (ustekinumab-auub), a biosimilar for the popular drug Stelara. According to the FDA announcement, the most serious side effect of Wezlana is infection because the prescription affects your immune response.

FDA 110
article thumbnail

Biogen’s shares surge again as FDA hurries Alzheimer’s drug review

pharmaphorum

Biogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted a clinical trial dossier and granted a fast Priority Review. The FDA reserves these quick reviews for drugs that have the potential to improve care standards for serious diseases.

FDA 105